课题基金 / 基金详情

Evaluation of hyaluronic acid as a marker of hepatic sinusoidal endothelial cell disorder in chronic liver injury

Evaluation of hyaluronic acid as a marker of hepatic sinusoidal endothelial cell disorder in chronic liver injury
透明质酸作为慢性肝损伤肝窦内皮细胞紊乱标志物的评价
批准号:
06670594
负责人:
UENO Takato
金额:
$1.15万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1994
资助国家:
日本
项目状态:
已结题
起止时间:
1994 至 1995

项目摘要

项目成果

UENO Takato的其他基金

相似基金

相关文献

中文摘要
翻译
血清透明质酸(HA)主要由肝窦内皮细胞(SEC)降解。在肝硬变中,肝窦毛细血管形成使SEC中HA的结合和降解减少,从而导致血清HA浓度升高。本研究以硫代乙酰胺(TAA)诱导慢性肝损伤模型大鼠为模型,以生理盐水为对照,探讨血清透明质酸(HA)水平是否为慢性肝损伤SEC紊乱的有用指标。测定TAA组和对照组大鼠血清HA水平和肝组织中14>C-HA放射性水平。在TAA治疗0、4、8、12、16周大鼠的培养SEC中,1)观察SEC.2的窗孔;2)检测抗CD44的免疫荧光强度;3)测定血清HA水平和肝组织中C-HA的结合量。随着慢性肝损伤的进展,SEC中CD-44的数量、孔隙率和表达均呈下降趋势,以肝硬化组最低。此外,肝硬化组与SEC的结合量明显低于对照组,提示慢性肝损伤时血HA浓度升高主要是由于SEC的HA受体减少,从而导致HA与细胞的结合量减少所致。
英文摘要
Most of the serum hyaluronic acid (HA) is degraded by hepatic sinusoidal endothelial cells (SEC). In liver cirrhosis, the bindig and degradation of HA in SEC are considered to be reduced by development of hepatic sinusoidal capillarization, resulting in high serum HA concentration. The aim of this study is to clarify whether serum HA level is an useful marker of SEC disorder in chronic liver injury.Chronic liver injury model rats were induced by thioacetamide (TAA) administration and control rats by physiologic saline. Serum HA levels and ^<14>C-HA radioactivity of liver tissues in TAA and control rats were measured. In cultured SEC obtained from 0,4,8,12 and 16-week TAA treated rats, 1) the observation of fenestrae in SEC.2) the immunofluorescent intensity of anti-CD44, and 3) the amount of ^<14>C-HA binding were determined.Serum HA levels ad ^<14>C-HA radioactivity of liver tissues increased with progression of chronic liver injury, and were the highest in liver cirrhosis. The number, porosity and expression of CD-44 in SEC decreased with progression of chronic liver injury and were the lowest in liver cirrhosis. Moreover, the amount of ^<14>C-HA binding to SEC significantly decreased in liver cirrhosis compared with the controls.These results indicate that the elevation of the blood HA concentration in chronic liver injury mainly occurs from a reduction in HA receptors of SEC and a consequent reduction in the amount of HA binding to the cells.
期刊论文(51)
专著(0)
科研奖励(0)
会议论文
上野隆登: "肝臓フォーラム′94記録集" 医事出版社, 199 (1994)
上野隆人:《肝脏论坛94记录集》伊治出版,199(1994)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Takato Ueno: "Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C" Hepato-Gastroenterology. 42. 522-527 (1995)
Takato Ueno:“血清透明质酸可以预测慢性丙型肝炎患者对干扰素-α 治疗的反应”肝胃肠病学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Motoaki Kin: "Sinusoidal capillarization in small hepatocellular carcinoma" Pathology International. 44. 771-778 (1994)
Motoaki Kin:“小肝细胞癌中的正弦毛细血管化”国际病理学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Takato Ueno: "Liver fibrotic markers" Kan Tan Sui. 31 (3). 443-450 (1995)
Takato Ueno:“肝纤维化标志物”Kan Tan Sui。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 27 条
    Whether methylated-(3")-epigallocatechin gallate is useful for the therapy of NASH(nonalcoholic steatohepatitis)?
    • 批准号:
      21590864
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2009
    • 负责人:
      UENO Takato
    • 依托单位:
    Research for usefulness of intestinal peptide, PYY_<3-36> for therapeutic agents of fatty liver and NASH
    • 批准号:
      16590650
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.18万
    • 财政年份:
      2004
    • 负责人:
      UENO Takato
    • 依托单位:
    ROLE OF PPARα HUMAN HEPATIC STELLATE CELL AND HEPATOMA CELL
    • 批准号:
      12670534
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.11万
    • 财政年份:
      2000
    • 负责人:
      UENO Takato
    • 依托单位:
    Morphologic study on Ito cell (Fat-storing cell) contractility
    • 批准号:
      02670330
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $1.54万
    • 财政年份:
      1990
    • 负责人:
      UENO Takato
    • 依托单位:
    海外基金